Pioglitazone to treat fatigue in hormone-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether pioglitazone can reduce fatigue in people with certain types of breast cancer. You may be eligible if your cancer is estrogen- and progesterone-positive (ER+/PR+) and you plan surgery soon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed breast cancer that is ER+ and PR+ and HER2-negative
- You have had no prior treatments except chemotherapy given before surgery (neoadjuvant)
- You have surgery (mastectomy) planned within 2 weeks of starting the study medicine
- You do not have diabetes and are not taking glucose-lowering medications
- Your blood tests (blood count, kidney, liver, and fasting blood sugar) are within normal ranges
- You can understand the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.